The reviews will continue while the company completes its phase III clinical trials in the U.K. and U.S. of its recombinant protein-based vaccine candidate.

To date, Novavax has begun a rolling review with the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada.

Novavax to supply Switzerland with 6M doses of COVID-19 vaccine
Novavax has agreed to supply the country of Switzerland with 6 million doses of its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax to produce Canadian supply of COVID-19 vaccine in Canada
Novavax has signed a memorandum of understanding with the Canadian government to produce the company's protein-based COVID-19 vaccine candidate, NVX-CoV2373,...

Novavax COVID-19 vaccine phase III trial indicates up to 89% efficacy
Novavax announced that its protein-based COVID-19 vaccine candidate, NVX-CoV2373, met the primary end point in a U.K. phase III clinical trial, achieving...

Canada ups COVID-19 vaccine order from Novavax to 76M doses
Novavax has finalized an agreement with the Canadian government to supply up to 76 million doses of NVX-CoV2373, a recombinant protein-based COVID-19...